Phase Ia trial of ACH 3102 in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Odalasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 23 Apr 2013 Status changed from recruiting to completed, based on information in Achillion Pharmaceuticals media releases.
- 27 Sep 2012 To date, 42 volunteers have received single dose ACH 3102 and 32 volunteers have received multiple-dose treatment, according to an Achillion Pharmaceuticals media release.
- 07 Aug 2012 Preliminary results published in an Achillion Pharmaceuticals media release.